Citation Information :
Karmakar S, Sharma P, Gupta VB, Harish A. A Pulmonologist Perspective in Post-COVID-19 Fungal Lung Infection: Data from Tertiary Institute. Indian J Chest Dis Allied Sci 2024; 66 (1):11-14.
Invasive fungal disease (IFD) is a serious complication of coronavirus disease-2019 (COVID-19), with a high mortality rate. This study aimed to determine the incidence, risk factors, and impact of IFD in adult moderate to severe COVID-19 patients. A retrospective study was conducted of 44 patients with a recent history of moderate to severe COVID-19 pneumonia and radiological evidence of cavitary lung disease. Bronchoalveolar lavage (BAL) galactomannan, fungal smear and culture, and histopathological examination of transbronchial lung biopsy (TBLB) were performed. The mean age of the patients was 59.68 years. The most common comorbidity was diabetes (45.4%). Bronchoalveolar lavage galactomannan was positive in 45.4% of patients. The most common imaging finding was cavitating consolidation. Total of 12 patients (27.27%) died during the follow-up period. The study found that BAL galactomannan can be a useful diagnostic tool for IFD in post-COVID-19 patients. Cavitating consolidation is a common imaging finding in patients with IFD. Patients with cavitating consolidation who have been recently discharged from the hospital with COVID-19 should be considered for empirical antifungal therapy. This study provides important insights into the diagnosis and management of IFD in post-COVID-19 patients. These findings can help clinicians to identify and treat patients with these infections more effectively.
Muthu V, Agarwal R, Dhooria S, et al. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin Microbiol Infect 2021;27(4):538–549. DOI: 10.1016/j.cmi.2020.12.035.
Maschmeyer G, Carratalà J, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009;45(14):2462–2472. DOI: https://doi.org/10.1016/j.ejca.2009. 05.001.
Nguyen MH, Jaber R, Leather HL, et al. Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol 2007;45(9):2787–2792. DOI: 10.1128/JCM.00716-07.
D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: Analytical and clinical validity. J Clin Microbiol 2012;50(4):1258–1263. DOI: https://doi.org/10.1128/JCM.06423-11.
Racil Z, Kocmanova I, Toskova M, et al. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis 2011;15(12):e874–e881. DOI: 10.1016/j.ijid.2011.09.011.
Da Nam B, Kim TJ, Lee KS, et al. Pulmonary mucormycosis: Serial morphologic changes on computed tomography correlate with clinical and pathologic findings. Eur Radiol 2018;28(2):788–795. DOI: 10.1007/s00330-017-5007-5.
Garg M, Prabhakar N, Muthu V, et al. CT findings of COVID-19–associated pulmonary mucormycosis: A case series and literature review. Radiology 2022;302(1):214–217. DOI: 10.1148/radiol.2021211583.
Johnson AK, Ghazarian Z, Cendrowski KD, et al. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021;32:64–67. DOI: 10.1016/j.mmcr.2021.03.006.
Bellanger AP, Navellou JC, Lepiller Q, et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now 2021;51(7):633–635. DOI: 10.1016/j.idnow.2021.01.010.
